<DOC>
	<DOCNO>NCT00436722</DOCNO>
	<brief_summary>This randomize , control trial liver transplantation conventional immunosuppressive treatment compare therapeutic strategy consist pre-transplant antibody-mediated T cell depletion follow reduce calcineurin inhibitor usage . The work hypothesis antibody induction follow calcineurin inhibitor minimization may promote development tolerogenic mechanism allow eventual withdrawal immunosuppressive therapy .</brief_summary>
	<brief_title>Induction Treatment Followed Immunosuppression Withdrawal Liver Transplantation : A Comparative Trial</brief_title>
	<detailed_description>This open-label randomise control study patient randomise accord 1:1 ratio receive conventional immunosuppressive treatment induction treatment plus reduced tacrolimus dosage . All transplant patient enrol study follow 12 month evaluate accord intention-to-treat approach . - Specific Aim 1 : To determine proportion liver recipient tacrolimus usage significantly reduce 1 year transplantation . Patients consider successfully receive reduce tacrolimus regimen drug give single dose every day , administer single dose daily trough level &lt; 5ng/mL . - Specific Aim 2 : To determine effect induction treatment plus minimized immunosuppression graft patient survival . - Specific Aim 3 : To determine impact induction treatment plus minimized immunosuppression development : acute chronic allograft rejection , hepatitis C virus graft recurrence , opportunistic infection , bone fracture , kidney failure , tacrolimus-related neurotoxicity , dyslipidemia arterial hypertension . - Specific Aim 4 : To establish whether use ATG induction follow reduced dos tacrolimus differentially affect anti-donor immune response and/or promotes development T cell dependent immunoregulatory network . - Conventional immunosuppressive protocol : 1 . Methylprednisolone iv 500 mg laparotomy , 500 mg time reperfusion . 2 . Methylprednisolone iv accord follow schedule : postoperative day 1 200 mg , day 2 160mg , day 3 120 mg , day 4 80 mg , day 5 40 mg , thereafter 20 mg oral prednisone . 3 . Oral tacrolimus q12h start postoperative day 1 order reach trough drug level 10 15 ng/mL . These level maintain range first month transplantation . Subsequently , tacrolimus level gradually reduce follow : : month 1-3 : 8-15 ng/ml ; month 4-12 : 7-12 ng/ml ; afterwards : 5-10 ng/ml . 4 . Progressive prednisone withdrawal month 6 9 transplantation . 5 . Treatment acute rejection episode : accord conventional clinical protocol . All effort must do order histologically document rejection episode . Hence , empirical treatment avoid possible . - Induction protocol : 1 . ATG-Fresenius 9mg/kg pre-transplantation , precede administration 500 mg iv methylprednisolone . Infusion ATG-F start whenever surgeon confirm suitability graft , take place 6 hour . 2 . Oral tacrolimus q12h , start postoperative day 1 require dosage order reach drug level 5 12 ng/mL 3 . Reduction tacrolimus dosages start 3 month transplantation stable patient evidence graft rejection previous 60 day , accord follow protocol : - posttransplant month 3 : 1 dose per day - posttransplant month 6 : 1 dose every 48 hour - posttransplant month 9 : Â½ dose every 48 hour - posttransplant month 12 : evaluate possibility complete drug withdrawal alternatively establish optimal maintenance dose . 4 . Treatment acute rejection episode : mild moderate acute rejection episode : re-start 1-2 daily dos tacrolimus . Severe acute rejection episode mild moderate episode improve 10 day treatment : 1-2 daily dos tacrolimus plus methylprednisolone 0.5-1 g 3 day . Resolution rejection episode follow resumption mention protocol . If new rejection episode take place , treatment acute episode attempt reduce tacrolimus dosage attempt . In case rejection confirm liver biopsy . 5 . Patients suffer hepatitis C virus infection treat , unless alpha-interferon treatment consider . In case , daily tacrolimus administer . 6 . All patient receive CMV prophylaxis iv ganciclovir 14 day oral valganciclovir complete 3 month transplantation . - Sample collection study period In addition routine diagnostic test , enrol patient undergo following procedure : - Cryopreservation donor spleen cell measure anti-donor immune response . - HCV viral load quantification pre-transplantation post-transplant month 1 , 6 12 . - All patient undergo liver biopsy 1 year transplantation yearly thereafter . In addition , HCV positive patient undergo liver biopsy 3 month transplantation . A portion liver biopsy cryopreserved gene expression study . - Anti-donor anti-HCV T cell immune response quantify transplantation , 6 12 month transplantation gamma-interferon ELISpot assay . - Peripheral blood mononuclear cell harvest cryopreserved transplantation , 6 month 12 month transplantation perform gene expression flow cytometry study . - A sample recipient DNA cryopreserved perform DNA polymorphism study .</detailed_description>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<criteria>Age &gt; 18 year Recipient primary liver graft Absence exclusion criterion Pretransplant renal failure , define serum creatinine &gt; 1.5 mg/dL Severe pretransplant thrombopenia , define platelet &lt; 50000/mL Combined liverkidney transplantation Autoimmune hepatitis , primary biliary cirrhosis primary sclerosing cholangitis cause liver transplantation Chronic hepatic encephalopathy Living donor liver transplantation Recipient human immunodeficiency virus infection Severe pretransplant leukopenia , define &lt; 1500 leukocytes/mL</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2009</verification_date>
	<keyword>Liver</keyword>
	<keyword>Transplantation</keyword>
	<keyword>Tolerance</keyword>
	<keyword>Induction</keyword>
	<keyword>Tacrolimus</keyword>
	<keyword>Liver transplantation</keyword>
	<keyword>Adult</keyword>
</DOC>